In patients with non-small cell lung cancer (NSCLC), repotrectinib, the targeted drug shows effective results.
The results of the TRIDENT-1 trial, which will be presented on Friday at the 34th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, suggest that repotrectinib could be effective for treating ROS1 positive NSCLC, both in patients who have received other targeted treatments and in those who have not.
h2Clinical Trials in Non-Small Cell ...
In patients with non-small cell lung cancer (NSCLC), repotrectinib, the targeted drug shows effective results.
The results of the TRIDENT-1 trial, which will be presented on Friday at the 34th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, suggest that repotrectinib could be effective for treating ROS1 positive NSCLC, both in patients who have received other targeted treatments and in those who have not.
h2Clinical Trials in Non-Small Cell ...